跳至主要内容
临床试验/NCT06283056
NCT06283056已完成不适用

Radiofrequency Microneedling With Multi-Depth Targeting Per Insertion for The Treatment of Cellulite

InMode MD Ltd.4 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2022年6月16日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
48
试验地点
4
主要终点
Cellulite assessment based on Clinician Reported Photonumeric Cellulite Severity Scale

研究概览

简要总结

The aim of the study is to evaluate the safety and efficacy of Morpheus 8 Body 40-pin tip up to 7mm depth Applicator for subdermal treatment of cellulite appearance, skin laxity, and subcutaneous fat deposits.

详细描述

The aim of the study is to evaluate the safety and efficacy of Morpheus 8 Body 40-pin tip up to 7mm depth Applicator for subdermal treatment of cellulite appearance, skin laxity, and subcutaneous fat deposits.

Prospective, open-label, baseline-controlled, clinical study to evaluate the Morpheus8 device for treatment of cellulite, skin laxity, and subcutaneous fat deposits of the thighs.

Eligible subjects will undergo two treatments with the Morpheus8 device using the 3, 5 7 mm depths or sequential (Burst) mode, based on the treating physician's discretion.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Female subjects aged 18-65 (inclusive)
  • BMI interval: 18.5 ≤ BMI ≤ 30 (normal to overweight, but not obese).
  • Subject having cellulite grade 1-4 as graded using the Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS)
  • The patients should understand the information provided about the treatment, possible benefits and side effects, and sign the Informed Consent Form, (including the permission to use photography).
  • The patients should be willing to comply with the study procedure and schedule, including the follow up visit, and will refrain from using any other aesthetic treatment methods (i.e liposuction, any cellulite/circumference reduction treatments using medical devices, etc.) in the treatment area for the last 6 months and during the entire study period.
  • Females of Childbearing potential must be using an approved method of birth control. Subjects who are capable of becoming pregnant will undergo a urine pregnancy test.

排除标准

  • Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body.
  • Superficial permanent implant in the treated area such as metal plates and screws, metal piercing, silicone implants or an injected chemical substance.
  • Known sensitivity/allergy to Lidocaine
  • Current or history of skin cancer (remission of 5 years), or current condition of any other type of cancer, or pre-malignant moles.
  • Severe concurrent conditions, such as cardiac disorders, epilepsy, uncontrolled hypertension, and liver or kidney diseases.
  • Pregnancy and nursing or lactating.
  • History of bleeding coagulopathies or use of anticoagulants.
  • Chronic or current use of NSAIDs or other anti-inflammatory therapies (e.g., Ibuprofen, etc.)
  • Impaired immune system due to immunosuppressive diseases such as AIDS and HIV or use of immunosuppressive medications.
  • Any uncontrolled medical condition (i.e., endocrine disorders, diabetes, thyroid disfunction or hormonal virilization) that in the opinion of the investigator, the subject's safety may be compromised.
  • Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash.
  • History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin.
  • Use of Isotretinoin (Accutane®) within 6 months prior to treatment.
  • Any surgery or treatment such as laser or chemicals in treated area within 3-6 months prior to treatment or before complete healing.
  • Any medical condition that in the opinion of the investigator, such condition would compromise the safety of the subject or quality of the study data.
  • Current, or past participation in a clinical trial within the past 30 days.

研究组 & 干预措施

Device Treatment

Experimental

Eligible subjects will undergo two treatments with the Morpheus8 device using the 3, 5 7 mm depths or sequential (Burst) mode, based on the treating physician's discretion.

干预措施: Device treatment (Device)

结局指标

主要结局

Cellulite assessment based on Clinician Reported Photonumeric Cellulite Severity Scale

时间窗: 6 Months

Cellulite assessment based on Clinician Reported Photonumeric Cellulite Severity Scale (using pre (baseline) and post treatment Standard medical photography, having at least mean of one-unit improvement (1-point score reduction). 0 - None - No evident cellulite 1. \- Almost none - A few superficial dimples or ridges 2. \- Mild - Several dimples or ridges, of which most are superficial 3. \- Moderate - Many dimples or ridges, of which more are somewhat deep 4. \- Severe - A lot of dimples or ridges, of which many are deep, covering most of the skin area

Cellulite assessment based on DiBernardo Photonumeric Cellulite Severity Scale

时间窗: 6 Months

Cellulite assessment based on DiBernardo Photonumeric Cellulite Severity Scale using pre (baseline) and post-treatment Standard medical photography, having at least a mean of one-unit improvement (1-point score reduction). This 5-point photo numeric scale rates cellulite severity from "0" (none) to "4" (severe) from a clinician's perspective

Cellulite assessment based on Clinician Reported Photonumeric Cellulite Severity Scale

时间窗: 6 Months

Cellulite assessment based on Clinician Reported Photonumeric Cellulite Severity Scale (using pre (baseline) and post treatment Standard medical photography, having at least mean of one-unit improvement (1-point score reduction). 0 - None - No evident cellulite 1. \- Almost none - A few superficial dimples or ridges 2. \- Mild - Several dimples or ridges, of which most are superficial 3. \- Moderate - Many dimples or ridges, of which more are somewhat deep 4. \- Severe - A lot of dimples or ridges, of which many are deep, covering most of the skin area

Cellulite assessment based on DiBernardo Photonumeric Cellulite Severity Scale

时间窗: 6 Months

Cellulite assessment based on DiBernardo Photonumeric Cellulite Severity Scale using pre (baseline) and post-treatment Standard medical photography, having at least a mean of one-unit improvement (1-point score reduction). This 5-point photo numeric scale rates cellulite severity from "0" (none) to "4" (severe) from a clinician's perspective

次要结局

  • Investigator assessment of the skin appearance improvement(3 months)
  • Subject assessment of satisfaction(6 months)
  • Investigator assessment of the skin appearance(6 months)
  • Investigator assessment of the cellulite following subdermal Morpheus8 treatment(6 Months)
  • Subject assessment of improvement(6 months)
  • Investigator assessment of the skin appearance improvemen(1 month)

研究者

发起方
InMode MD Ltd.
申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验